VenoVision selected for MassChallenge's 2023 HealthTech Cohort

WILMINGTON, Del. - March 28, 2023 - PRLog -- VenoVision was selected to participate in the MassChallenge 2023 HealthTech Sprint. VenoVision was one of over 200 startup applications for this year's program.

"We're excited to join the MassChallenge 2023 HealthTech Sprint and start developing the partnerships across the healthcare system needed for clinical trials, regulatory strategy and reimbursement." – Jonathan Maron, President, VenoVision.

By participating in this accelerator, VenoVision will receive unrivaled access to a global network of partners, experts, and mentors. Throughout the program, the company will join 37 startups who will benefit from integration into healthcare ecosystems through MassChallenge partnerships, as well as Medicare and Medicaid curriculum by MITRE to support federal opportunities.

VenoVision will help improve therapeutic management, patient outcomes, and drive down the billions of dollars wasted every year on preventable perioperative deterioration and rehospitalization of those suffering, or at risk of, heart failure and other hemodynamic complications.

VenoVision was conceptualized in The Hebrew University's BioDesign program, a multidisciplinary, team-based approach to medical innovation under the supervision of Prof. Yaakov Nahmias, Ph.D., Prof. Dan Galai, Ph.D., and Prof. Dr. Tal Hasin, MD. Since then, it has completed a proof-of-concept clinical trial at Shaare Zedek Medical Center, Jerusalem, been granted its first patent in February 2022, was a MassChallenge Israel Finalist, and is Health Wildcatters Dallas Accelerator 2022 portfolio company.

Mr. Maron added, "VenoVision is proud to continue its development in the MassChallenge community, having made the transition from MassChallenge Israel 2021 Finalist to Delaware C-Corp and now participating in the HealthTech Sprint in the USA."

VenoVision will be working with MassChallenge to establish partnerships across clinical, regulatory and reimbursement pathways.

About VenoVision
VenoVision provides the missing non-invasive cardiological data and monitoring needed to reduce ICU admissions and hospitalizations for millions of heart failure and at-risk patients. VenoVision is a low cost, easy-to-use, imaging device and hemodynamic monitoring platform for the inpatient, outpatient and home settings. venovision.com.